BlackRock’s Calithera Biosciences, Inc CALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-83,839
| Closed | -$273K | – | 5849 |
|
|
2022
Q4 | $273K | Sell |
83,839
-185
| -0.2% | -$442 | ﹤0.01% | 4763 |
|
|
2022
Q3 | $246K | Sell |
84,024
-9,367
| -10% | -$32K | ﹤0.01% | 4923 |
|
|
2022
Q2 | $231K | Sell |
93,391
-2,909
| -3% | -$13.5K | ﹤0.01% | 4998 |
|
|
2022
Q1 | $777K | Buy |
96,300
+363
| +0.4% | +$3.71K | ﹤0.01% | 4751 |
|
|
2021
Q4 | $1.28M | Sell |
95,937
-30,888
| -24% | -$776K | ﹤0.01% | 4577 |
|
|
2021
Q3 | $5.53M | Sell |
126,825
-12,980
| -9% | -$560K | ﹤0.01% | 3919 |
|
|
2021
Q2 | $5.84M | Sell |
139,805
-183,931
| -57% | -$8.08M | ﹤0.01% | 3827 |
|
|
2021
Q1 | $15.7M | Buy |
323,736
+40,316
| +14% | +$2.35M | ﹤0.01% | 3313 |
|
|
2020
Q4 | $27.8M | Buy |
283,420
+27,052
| +11% | +$2.37M | ﹤0.01% | 2831 |
|
|
2020
Q3 | $17.7M | Sell |
256,368
-1,178
| -0.5% | -$103K | ﹤0.01% | 2930 |
|
|
2020
Q2 | $27.2M | Buy |
257,546
+52,440
| +26% | +$6.23M | ﹤0.01% | 2637 |
|
|
2020
Q1 | $18.2M | Sell |
205,106
-270
| -0.1% | -$32.2K | ﹤0.01% | 2653 |
|
|
2019
Q4 | $23.5M | Sell |
205,376
-651
| -0.3% | -$49K | ﹤0.01% | 2792 |
|
|
2019
Q3 | $12.7M | Buy |
206,027
+44,589
| +28% | +$3.57M | ﹤0.01% | 3088 |
|
|
2019
Q2 | $12.6M | Buy |
161,438
+8,781
| +6% | +$997K | ﹤0.01% | 3115 |
|
|
2019
Q1 | $20.6M | Buy |
152,657
+148
| +0.1% | +$15.5K | ﹤0.01% | 2733 |
|
|
2018
Q4 | $12.2M | Sell |
152,509
-15,037
| -9% | -$1.48M | ﹤0.01% | 2982 |
|
|
2018
Q3 | $17.6M | Buy |
167,546
+230
| +0.1% | +$21.9K | ﹤0.01% | 2938 |
|
|
2018
Q2 | $16.7M | Buy |
167,316
+5,864
| +4% | +$664K | ﹤0.01% | 2964 |
|
|
2018
Q1 | $20.3M | Buy |
161,452
+17,138
| +12% | +$2.67M | ﹤0.01% | 2768 |
|
|
2017
Q4 | $24.1M | Buy |
144,314
+39,241
| +37% | +$10M | ﹤0.01% | 2680 |
|
|
2017
Q3 | $33.1M | Buy |
105,073
+2,036
| +2% | +$642K | ﹤0.01% | 2526 |
|
|
2017
Q2 | $30.6M | Buy |
103,037
+87,859
| +579% | +$23.5M | ﹤0.01% | 2539 |
|
|
2017
Q1 | $3.51M | Buy |
+15,178
| New | +$2.62M | ﹤0.01% | 3494 |
|
|
2016
Q2 | – | Sell |
-19
| Closed | -$2K | – | 3856 |
|
|
2016
Q1 | $2K | Buy |
19
+8
| +73% | +$906 | ﹤0.01% | 3479 |
|
|
2015
Q4 | $2K | Hold |
11
| – | – | ﹤0.01% | 3342 |
|
|
2015
Q3 | $1K | Hold |
11
| – | – | ﹤0.01% | 3192 |
|
|
2015
Q2 | $2K | Buy |
+11
| New | +$2.55K | ﹤0.01% | 3212 |
|
Other funds holding CALA
BlackRock's CALA Position: Q1 2023 in Review
BlackRock sold out of Calithera Biosciences, Inc (CALA) in Q1 2023, closing a stake of 83,839 shares — an estimated $273K sold.
BlackRock first reported a position in CALA in Q2 2015 and held it in 28 quarters. The position peaked at $33.1M in Q3 2017. 2 funds tracked by Wall St. Rank hold CALA as of Q1 2023.
- BlackRock reported no remaining Calithera Biosciences, Inc position as of Q1 2023 after selling out during the quarter.
- BlackRock sold 83,839 Calithera Biosciences, Inc shares in Q1 2023, an estimated $273K.
- BlackRock first reported a position in Calithera Biosciences, Inc in Q2 2015 and held it in 28 quarters.
- BlackRock's Calithera Biosciences, Inc position peaked at $33.1M in Q3 2017.
- 2 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2023.
Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.